Type 1 Diabetes

A cross-sectional analysis of Medicare and commercial insurer spending suggests the in-state biosimilar production plan could be substantial in savings even after insulin cost rebates.

An analysis of NHANES data from 2009-2020 suggest approximately 75% of people with diabetes in the US were not at the American Diabetes Association-recommended HbA1c target of less than 7%.

An analysis of data from the TEDDY study suggests increased levels of moderate to vigorous physical activity could reduce risk of progression to type 1 diabetes in multiple islet autoantibody-positive children.

An analysis of data from nearly 100 adults with type 1 diabetes details associations between chronotypes and improved well-being in people with diabetes.

Pooling data from the TODAY and SEARCH studies, new research offers an overview of the challenges in access to care and outcomes among adolescents with type 1 and type 2 diabetes

An analysis of more than 1.8 million mother-offspring pairs offers new insight into a potential association between exposure to maternal depression/anxiety during pregnancy and risk of type 1 diabetes in offspring during adolescence.

An analysis of more than 4000 people from a university hospital in Japan details the impact of the COVID-19 pandemic on glycemic control and lipid profiles among people with diabetes.

In this episode, hosts offer their reaction to topline data from the SURMOUNT-2 trial examining tirzepatide for weight management in T2D, the FDA's clearance of the Omnipod GO device, and results of the CLVer trial.

Each month, our editorial staff compiles a recap of the top news in endocrinology from the past month. Our April 2023 month in review features top new studies, FDA approvals, and an overview of news surrounding Abbott readers.

Drs Diana Isaacs and Natalie Bellini emphasize the need for early detection of diabetic kidney disease through the monitoring of cardiometabolic risk factors.

George Bakris, MD, shares best practices for co-management and providing comprehensive care for patients with diabetic kidney disease.

Dr George Bakris reviews the clinical trial data for finerenone and provides insights on treatment selection, including the potential benefits of combination therapy with finerenone and SGLT2 inhibitors, in managing diabetic kidney disease.

Dr George Bakris elaborates on the risk factors, monitoring, treatment objectives, and the impact of diet and exercise in preventing the progression of diabetic kidney disease.

On April 21, 2023, Medtronic announced the long-awaited US approval of their MiniMed 780G System with Smart Guard Technology and the Guardian 4 Sensor, which has been available in Europe for nearly 3 years.

An analysis of an ethnically diverse cohort in London found African Caribbean people experienced a 39% greater risk of sight-threatening DR, independent of traditional risk factors.

A meta-analysis of trials examining use of the t:slim X2 insulin pump with Control-IQ technology, results of the study indicate use of the hybrid closed loop technology was associated with improvements in glycemic control, regardless of patient age, race, or previous CGM use.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss the implications of increased CGM access through a recent CMS expansion and take a deep dive into the latest Abbott news, including dispelling misconceptions surrounding the recall announcement.

Announced on April 14, the clearance allows for FreeStyle Libre 3 users to obtain real-time glucose readings on a large, easy-to-see screen directly from their back of arm sensors.

An analysis of data from national registries in Sweden offers an overview of associations between psychiatric disorders and educational milestone attainment among youth with type 1 diabetes.

A new pilot study assessing the shelf life of insulin when stored at room temperature during the summer in India suggests most insulins maintained 95% potency or greater at 4 months relative to refrigerated insulin.

Announced on April 6, the recall, which is the most serious of its kind, includes all Readers used with the FreeStyle Libre, FreeStyle Libre 14 day, and FreeStyle Libre 2 Flash Glucose Monitoring Systems distributed from November 2017-February 2023, which totals more than 4 million devices in the US.

Drs Diana Isaacs and Natalie Bellini summarize the key takeaways on screening for pediatric and adult-onset type 1 diabetes and strategies to improve screening.

An expert pediatric endocrinologist discusses best practices for referring patients to a specialist in type 1 diabetes, as well as the potential of new therapies in delaying the progression of the disease.

Dr Fran Cogen discusses the screening of autoantibodies for type 1 diabetes and provides insights on how to interpret the results of the screening tests.

Dr Fran Cogen emphasizes the importance of early screening and detection of type 1 diabetes to prevent the adverse health effects of diabetic ketoacidosis.